Provided by Tiger Fintech (Singapore) Pte. Ltd.

Ionis Pharmaceuticals

29.70
+0.13000.44%
Post-market: 29.58-0.1200-0.40%18:58 EDT
Volume:1.02M
Turnover:30.06M
Market Cap:4.72B
PE:-9.78
High:29.90
Open:29.38
Low:28.87
Close:29.57
Loading ...

Press Release: Ionis to hold first quarter 2025 financial results webcast

Dow Jones
·
16 Apr

Ionis Pharmaceuticals Price Target Maintained With a $60.00/Share by Needham

Dow Jones
·
15 Apr

Ionis Pharmaceuticals price target lowered to $52 from $55 at Morgan Stanley

TIPRANKS
·
11 Apr

Morgan Stanley Keeps Their Hold Rating on Ionis Pharmaceuticals (IONS)

TIPRANKS
·
11 Apr

Ionis Pharmaceuticals (IONS) Surges 8.9%: Is This an Indication of Further Gains?

Zacks
·
10 Apr

Ionis Pharmaceuticals Price Target Maintained With a $60.00/Share by Needham

Dow Jones
·
08 Apr

BUZZ-U.S. STOCKS ON THE MOVE-Janover, AMC Entertainment, U.S. Steel

Reuters
·
07 Apr

BUZZ-H.C. Wainwright initiates coverage for Ionis  Pharma with 'buy' rating citing pending drug launches

Reuters
·
07 Apr

HC Wainwright Initiates Ionis Pharmaceuticals With Buy Rating, $45 Price Target

MT Newswires Live
·
07 Apr

Ionis Pharmaceuticals Initiated at Buy by HC Wainwright & Co.

Dow Jones
·
07 Apr

Ionis Pharmaceuticals, Inc. : H.c. Wainwright Initiates Coverage With Buy Rating and Target Price $45

THOMSON REUTERS
·
07 Apr

Ionis Pharmaceuticals management to meet with Oppenheimer

TIPRANKS
·
05 Apr

Ionis to host expert panel discussion on sHTG

Business Wire
·
03 Apr

Biogen's BIIB080 Gets FDA Fast-Track Designation in Alzheimer's Disease

Dow Jones
·
02 Apr

Ionis Pharmaceuticals Initiated at Neutral by Redburn Atlantic

Dow Jones
·
31 Mar

Redburn Atlantic Initiates Ionis Pharmaceuticals at Neutral With $39 Price Target

MT Newswires Live
·
31 Mar

Ionis to present at upcoming investor conferences

Business Wire
·
31 Mar

Catalyst (CPRX) Up 14.7% Since Last Earnings Report: Can It Continue?

Zacks
·
28 Mar

IONS Out-Licenses ex-U.S. Rights for Rare Disease Drug Tryngolza to Sobi

Zacks
·
27 Mar

Ionis Partners With Sobi to Commercialize Familial Chylomicronemia Syndrome Treatment Outside US

MT Newswires Live
·
26 Mar